Radioligand therapy using [(177)Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis

BACKGROUND: Radioligand therapy with [(177)Lu]Lu-PSMA-617 is efficacious for the treatment of patients with metastasized castration-resistant prostate cancer (mCRPC). Various studies have evaluated the efficacy and safety of [(177)Lu]Lu-PSMA-617 using a dose of 6.0 GBq and an 8-week therapy interval...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Eur J Nucl Med Mol Imaging
Prif Awduron: Seifert, Robert, Kessel, Katharina, Schlack, Katrin, Weckesser, Matthias, Bögemann, Martin, Rahbar, Kambiz
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer Berlin Heidelberg 2020
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7338828/
https://ncbi.nlm.nih.gov/pubmed/32062682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-020-04703-3
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg